Collegium Pharmaceutical (FRA:354) FFO


FRA:354 Collegium Pharmaceutical Inc FRA:354
75 GF Score
Price €31.20
GF Value €37.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical FFO?

FFO (Funds from operations) only applies to REITs.

FRA:354
75GF Score
Collegium Pharmaceutical Inc FRA:354
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €31.20 is trading 16.1% below its estimated GF Value™ of €37.18. GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.

Key valuation signals for FRA:354:

  • FFO:
  • GF Value™: €37.18 vs. price of €31.20 (16.1% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
75GF Score

Get the complete analysis for FRA:354

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.20
Price
€37.18
GF Value